Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6655342 | 0.82 | SLC2A1 (0.41) | PREPALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL2500559 | 0.81 | ELANE (0.52) | PREPCA12CA1CA9LMNA | |
| SCHEMBL8699124 | 0.81 | MAPT (0.40) | PREPALDH1A1CYP1A2LMNAHTT | |
| SCHEMBL8379284 | 0.81 | PREP (0.40) | PREPALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL2099038 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP1A2LMNAHTTSMN1; SMN2 | |
| SCHEMBL6542930 | 0.80 | CA1 (0.52) | PREPALDH1A1CA12CA1CA9 | |
| SCHEMBL936407 | 0.80 | MAPT (0.53) | PREPALDH1A1CA12CA1CA9 | |
| SCHEMBL8382753 | 0.79 | TRPA1 (0.44) | PREPALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL8644671 | 0.79 | PREP (0.37) | PREPALDH1A1CYP1A2CA12CA1 | |
| SCHEMBL12339125 | 0.78 | PARP10 (0.53) | PREPALDH1A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238396-A1 | NMDA LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-7875626-B2 | 3,3,3-trifluoropropane-1-sulfonic acid 4-[1-(2-chlorophenyl)-3-methyl-4-oxo-5-piperidin-1-yl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine-2-yl]phenyl ester; treatment of obesity, psychiatric and neurological disorders | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| EP-1937679-B1 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-20080312269-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008096151-A1 | PHARMACEUTICAL COMPOSITIONS OF CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-5710168-A | 2-piperidino-1-alkanol derivatives as neuroprotective agents | PFIZER INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5527912-A | USEFUL INTREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5391742-A | Intermediates for 2-piperidino-1-alkanols | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5338754-A | 2-pyrrolidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1994-08-16 | — | — | US | disclosed |
| US-5272160-A | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1993-12-21 | — | — | US | disclosed |
| US-5185343-A | NORTROPYL-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1990014087-A1 | 2-PIPERIDINO-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1990-11-29 | — | — | WO | disclosed |
| WO-1990014088-A1 | 2-PIPERIDINO-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1990-11-29 | — | — | WO | disclosed |
| EP-0398578-A2 | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC. (US) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009513-A1 | Therapeutic agents | NLN, GPR119, FABP4 | PREP 1416/4885ALDH1A1 403/4885CYP1A2 749/4885 |
| US-20080312269-A1 | Therapeutic Agents | NLN, GRIN2C, GPR119 | PREP 1565/4885ALDH1A1 612/4885CYP1A2 1230/4885 |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | CNR1, CNR2, GPR18 | PREP 2578/4885ALDH1A1 4335/4885CYP1A2 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.